Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Results by year

Table representation of search results timeline featuring number of search results per year.

Year Number of Results
2012 1
2015 4
2016 2
2018 3
2022 1
2023 2
2024 0

Text availability

Article attribute

Article type

Publication date

Search Results

13 results

Results by year

Citations

2 articles found by citation matching

Search results

Filters applied: . Clear all
Page 1
Thymosin beta 4 and the eye: the journey from bench to bedside.
Sosne G. Sosne G. Expert Opin Biol Ther. 2018 Jul;18(sup1):99-104. doi: 10.1080/14712598.2018.1486818. Expert Opin Biol Ther. 2018. PMID: 30063853 Review.
Thymosin beta 4 (Tbeta4) has important applications in ocular repair and Phase 3 clinical trials using Tbeta4 to treat dry eye and neurotrophic keratopathy are currently ongoing. ...Expert opinion: The electrifying possibility of Tbeta4 as a rev
Thymosin beta 4 (Tbeta4) has important applications in ocular repair and Phase 3 clinical trials using Tbeta4 to treat
Thymosin Beta 4: A Potential Novel Therapy for Neurotrophic Keratopathy, Dry Eye, and Ocular Surface Diseases.
Sosne G, Rimmer D, Kleinman HK, Ousler G. Sosne G, et al. Vitam Horm. 2016;102:277-306. doi: 10.1016/bs.vh.2016.04.012. Epub 2016 Jul 5. Vitam Horm. 2016. PMID: 27450739 Review.
Chronic ocular surface diseases such as dry eye, blepharitis, and neurotrophic keratopathies represent a significant and a growing therapeutic challenge. ...A focus on treatments that reduce the inflammatory responses while accelerating corneal epithelial growth wou …
Chronic ocular surface diseases such as dry eye, blepharitis, and neurotrophic keratopathies represent a significant and a gro …
Thymosin beta 4 ophthalmic solution for dry eye: a randomized, placebo-controlled, Phase II clinical trial conducted using the controlled adverse environment (CAE) model.
Sosne G, Ousler GW. Sosne G, et al. Clin Ophthalmol. 2015 May 20;9:877-84. doi: 10.2147/OPTH.S80954. eCollection 2015. Clin Ophthalmol. 2015. PMID: 26056426 Free PMC article.
BACKGROUND: The purpose of this study was to evaluate the safety and efficacy of thymosin beta 4 ophthalmic solution (RGN-259; Tbeta4) in subjects with moderate to severe dry eye using the CAE model. ...CONCLUSION: This study confirms the effica …
BACKGROUND: The purpose of this study was to evaluate the safety and efficacy of thymosin beta 4 ophthalmic solution (R …
Thymosin beta 4: A potential novel adjunct treatment for bacterial keratitis.
Sosne G, Berger EA. Sosne G, et al. Int Immunopharmacol. 2023 May;118:109953. doi: 10.1016/j.intimp.2023.109953. Epub 2023 Apr 3. Int Immunopharmacol. 2023. PMID: 37018981 Free PMC article.
To this end, treatments are needed that both regulate the inflammatory response and promote corneal wound healing to resolve visual disturbances and improve quality of life. Thymosin beta 4 is a small, naturally occurring 43-amino-acid protein that promotes w …
To this end, treatments are needed that both regulate the inflammatory response and promote corneal wound healing to resolve visual disturba …
Thymosin beta4: a potential novel dry eye therapy.
Sosne G, Qiu P, Ousler GW 3rd, Dunn SP, Crockford D. Sosne G, et al. Ann N Y Acad Sci. 2012 Oct;1270:45-50. doi: 10.1111/j.1749-6632.2012.06682.x. Ann N Y Acad Sci. 2012. PMID: 23050816 Review.
The purpose of this manuscript is to review the clinical entity of dry eye syndrome (DES) and to provide a scientific basis and rationale for the usage of thymosin beta 4 (Tbeta4) as a novel therapy for DES. ...Based on previous studies, there i …
The purpose of this manuscript is to review the clinical entity of dry eye syndrome (DES) and to provide a scientific basis an …
Primary Mechanisms of Thymosin beta4 Repair Activity in Dry Eye Disorders and Other Tissue Injuries.
Sosne G, Kleinman HK. Sosne G, et al. Invest Ophthalmol Vis Sci. 2015 Aug;56(9):5110-7. doi: 10.1167/iovs.15-16890. Invest Ophthalmol Vis Sci. 2015. PMID: 26241398 Review.
Dry eye disorders are becoming more common due to many causes, including an aging population, increased pollution, and postrefractive surgery. ...We will also speculate on additional mechanisms that might promote eye repair based on data from other tissue inj
Dry eye disorders are becoming more common due to many causes, including an aging population, increased pollution, and postref
Thymosin β4 Alleviates Autoimmune Dacryoadenitis via Suppressing Th17 Cell Response.
Zhao X, Li N, Yang N, Mi B, Dang W, Sun D, Ma S, Nian H, Wei R. Zhao X, et al. Invest Ophthalmol Vis Sci. 2023 Aug 1;64(11):3. doi: 10.1167/iovs.64.11.3. Invest Ophthalmol Vis Sci. 2023. PMID: 37531112 Free PMC article.
PURPOSE: We investigated the therapeutic effect of recombinant thymosin beta4 (rTbeta4) on rabbit autoimmune dacryoadenitis, an animal model of SS dry eye, and explore its mechanisms. METHODS: Rabbits were treated topically with rTbeta4 or PBS solution after disease …
PURPOSE: We investigated the therapeutic effect of recombinant thymosin beta4 (rTbeta4) on rabbit autoimmune dacryoadenitis, an animal model …
Thymosin beta4 significantly improves signs and symptoms of severe dry eye in a phase 2 randomized trial.
Sosne G, Dunn SP, Kim C. Sosne G, et al. Cornea. 2015 May;34(5):491-6. doi: 10.1097/ICO.0000000000000379. Cornea. 2015. PMID: 25826322 Clinical Trial.
PURPOSE: Standard therapies for severe dry eye are limited and fail to resolve the problem. The purpose of this study was to evaluate the safety and efficacy of Thymosin beta4 eye drops (RGN-259) as a novel therapy for severe dry eye disease (in …
PURPOSE: Standard therapies for severe dry eye are limited and fail to resolve the problem. The purpose of this study was to e …
Thymosin beta4 significantly reduces the signs of dryness in a murine controlled adverse environment model of experimental dry eye.
Sosne G, Kim C, Kleinman HK. Sosne G, et al. Expert Opin Biol Ther. 2015;15 Suppl 1:S155-61. doi: 10.1517/14712598.2015.1019858. Epub 2015 Jun 22. Expert Opin Biol Ther. 2015. PMID: 26096547
OBJECTIVE: Dry eye syndrome is a common condition that affects up to 20% of the population aged 45 and older. ...CONCLUSIONS: Tbeta4 has the potential to be an important new effective therapeutic for dry eye....
OBJECTIVE: Dry eye syndrome is a common condition that affects up to 20% of the population aged 45 and older. ...CONCLUSIONS: …
13 results